// https://github.com/dustypomerleau/eye-notes

RVO

  CRVO risk factors
    age
    metabolic syndrome
      obesity
      HTN
      DM
      hyperlipidemia
    atherosclerosis
    CVA
    hyperviscosity syndromes
    thrombophilias
    smoking
    uveitis
    vasculitis
    OHTN
    glaucoma
    ocular compression
      orbital mass

    BRVO risk factors
      much less established
      likely include
        metabolic syndrome
        atherosclerosis
      may not include
        CRVO ocular risk factors


//


  DDx for a young patient with CRVO

    infectious
      viral
        HIV
      bacterial
        TB
        syphilis

    inflammatory
      inflammatory
        sarcoid
      autoimmune
        lupus

    idiopathic

    vascular
      vascular
        HTN
      hypercoagulable
        pregnancy
        hormonal contraceptives
        hyperhomocysteinemia
        protein C or S deficiency
        lupus anticoagulant
        anticardiolipin Ab
        antiphospholipid Ab
        factor 5 Leiden
        antithrombin 3 deficiency
        dysfibrinogenemias

    neoplastic
      hematologic
        polycythemia
        multiple myeloma
        dysproteinemias
          COMMON: Waldenstrom
            may also have asymptomatic peripheral hemorhages and occlusions

    DAMS
      drugs
        smoking
      medications
        hormonal contraceptives
      supplements & diet
        excess vitamin K intake

    endocrine
      endocrine
        DM
      metabolic
        hyperlipidemia
        obesity

    trauma


//


  workup for a young patient with RVO

    rule out by history
      smoking
      hormonal contraceptives
      vitamin K intake
      trauma

    rule out by vital signs
      HTN
      obesity

    possible testing
      HIV
        HIV testing
      sarcoid
        ACE
        lysozyme
        CXR
      TB
        Qgold
      syphilis
        RPR
        FTA-ABS
      lupus
        ANA
        ESR
        UEC
        urinalysis
      hematologic
        FBC
        hematology consultation
          hypercoagulable workup
            prothrombin time
            activated thromboplastin time
            platelets
            fibrinogen
            + all of the above from hypercoagulable DDx
        SPEP
      DM
        fasting glucose
      hyperlipidemia
        lipid profile


//


  treatment
    antiVEGF
      most do treat and extend
      choice of agent
        NEWTON study
          1 year results at ASRS 2016 (Khurana)
          20 patients previously treated with Lucentis or Avastin
          unable to extend beyond monthly
          switched to Eylea
          mean interval between injections increased from 6-10 weeks
          90+% went longer on Eylea
    steroids
      //...
      Triesence
      Ozurdex
      Zuprata
        suprachoroidal triamcinolone
        Zuprata + Eylea has finished phase 2
          reduced Eylea injection burden
        thought to have lower risk of IOP spikes
          wait for phase 3
    laser
      //...
      BRAVO + CRUISE
        scatter to NP does not reduce injections for CME
          similar data for DME in other studies
          BROADLY: scatter only for NV Â± VH


//


when you see a posterior segment with PDR OR RVO
  ALWAYS: consider the risk of NVG
